XML 23 R12.htm IDEA: XBRL DOCUMENT
v3.22.1

Accrued Expenses | 3 Months Ended
--- | ---
Mar. 31, 2022
Accrued Expenses. |
Accrued Expenses | 5. Accrued Expenses Accrued expenses consisted of the following (in thousands): ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | As of March 31, 2022 |  | As of December 31, 2021
Accrued clinical and regulatory | ​ | $ | 2,049 | ​ | $ | 1,236
Accrued contract manufacturing cost | ​ | ​ | 2,176 | ​ |  | 1,482
Accrued compensation | ​ | ​ | 1,218 | ​ | ​ | 1,027
Accrued research and development-other | ​ |  | 444 | ​ |  | 435
Total accrued expenses | ​ | $ | 5,887 | ​ | $ | 4,180
​

X
- Definition The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a),20,24) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_AccruedLiabilitiesCurrentAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration